[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"scn2a-dee\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:scn2a-dee":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100495944",false,"NCT05737784","A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy","A Seamless, Clinical Trial to Investigate the Safety and Efficacy of Multiple Doses of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy","Inclusion Criteria:\n\n* Has onset of seizures prior to 3 months of age.\n* Has a minimum weight of at least 10 kg at screening.\n* Has a documented SCN2A variant through genetic testing obtained via a laboratory accredited per Clinical Laboratory Improvement Amendments (CLIA) or College of American Pathologists (CAP) or equivalent.\n* Additional inclusion criteria apply and will be assessed by the study team\n\nExclusion Criteria:\n\n* Has any clinically significant or known pathogenic genetic variant other than in the SCN2A gene, or a genetic variant that may explain or contribute to the participant's epilepsy and\u002For developmental disorder.\n* Is taking more than 2 sodium channel blocking anti-seizure medications\n* Additional exclusion criteria apply and will be assessed by the study team","ALL","2 Years","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.",[27,28],"SCN2A-DEE","Epilepsy",[30,31,32,33,34,35,36],"Antisense Oligonucleotide","NaV1.2 Voltage-Gated Sodium Channel","Voltage-Gated Sodium Channel Blockers","SCN2A variant","Pediatric epilepsy","Developmental and Epileptic Encephalopathy","DEE","RECRUITING","2025-08-15",{"date":40,"type":41},"2025-08-21","ACTUAL",{"date":43,"type":41},"2023-04-13",{"date":45,"type":20},"2027-09",{"name":47,"class":48},"Praxis Precision Medicines","INDUSTRY",3,""]